FDC Consolidated Holdings makes strong ASX debut as shares surge 17pc after $969m float Business News Australia 08:50
Ascletis Submits Two IND Applications To The U.S. FDA For The Treatment Of Obesity: ASC36 Once-Monthly Injection, A Peptide Amylin Receptor Agonist, And ASC36_35 FDC Once-Monthly Injection, A Co-Formulation Of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 Drugs Discovery Online 08:22
FDC makes ASX debut with $969 million market valuation after $400 million IPO Proactive Investors (Australia) 06:54
